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Abstract
Single Gene Disorders (SGD) are still routinely diagnosed using PCR-based assays that
need to be developed and validated for each individual disease-specific gene fragment. The
TruSight One sequencing panel currently covers 12 Mb of genomic content, including 4813
genes associated with a clinical phenotype. When only a limited number of cells are avail-
able, whole genome amplification (WGA) is required prior to DNA target capture techniques
such as the TruSight One panel. In this study, we compared 4 different WGA methods in
combination with the TruSight One sequencing panel to perform single nucleotide polymor-
phism (SNP) genotyping starting from 3 micro-manipulated cells. This setting simulates clin-
ical settings such as day-5 blastocyst biopsy for Preimplantation Genetic Testing (PGT),
liquid biopsy of circulating tumor cells (CTCs) and cancer-cell profiling. Bulk cell samples
were processed alongside these WGA samples to serve as a performance reference. Tar-
get coverage, coverage uniformity and SNP calling accuracy obtained using any of the
WGA, is inferior to the results obtained on bulk cell samples. However, results after REPLI-g
come close. Compared to the other WGA methods, the method using REPLI-g WGA results
in a better coverage of the targeted genomic regions with a more uniform read depth. Con-
sequently, this method also results in a more accurate SNP calling and could be considered
for clinical genotyping of a limited number of cells.
Introduction
Several clinical settings such as PGT [1], liquid biopsy of CTCs and cancer-cell profiling of
tiny biopsies could benefit from a method allowing genotyping of large panels of SNPs, starting
with only a few cells as input. In this study, we simulate such a clinical setting by performing
genotyping of a SNP panel on micromanipulated cells from a cell line. The study aims to
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evaluate the performance of hybridization-capture-based target enrichment sequencing after
WGA on a few cells. More specifically, the study aims to provide performance data in a setting
mimicking SGD diagnosis in PGT, empowering future clinical feasibility studies in the in-
vitro fertilization (IVF) clinical practice.
Successful in-vitro fertilization may require preimplantation genetic testing (PGT) for the
selection of an embryo free of chromosomal aberrations and single gene disorders (SGD) car-
ried by its parents. Recently, shallow whole genome sequencing has proven to be useful for the
genome-wide detection of chromosomal aberrations in PGT [2–4]. SGDs on the other hand,
are still routinely diagnosed using PCR-based assays that are developed to target the specific
gene fragment(s) involved in a single or a limited number of genetic diseases [5]. Development
and validated application of these methods is time consuming. Established protocols often
require adjustments for couples carrying slightly different mutations [6].
Whole Genome Amplification (WGA) can be used to amplify the DNA of the limited num-
ber of cells that can be biopsied from blastocysts for PGT. This pre-amplified DNA can be
used to perform multiple PCR reactions, yielding multiple amplicons for the detection of dis-
ease-related mutations or insertions/deletions (indels). Massive parallel sequencing (MPS) can
be used to sequence a pool of these different amplicons [7]. The cost and timescale are reduced
by multiplexing different patient samples in a single sequencing run. Still, this approach
requires a specific PCR primer design for each disease-associated locus. WGA combined with
MPS could be used to sequence of the entire genome of the embryo, allowing simultaneous
screening of Single Nucleotide Polymorphisms (SNPs) and chromosomal aberrations. Whole
genome SNP analysis requires sequencing at high coverage for accurate detection, which cur-
rently is still too expensive for routine clinical applications.
The TruSight One Sequencing Panel (Illumina) targets 4,813 genes associated with known
clinical phenotypes and enables simultaneous screening for mutations in these genes in a sin-
gle sequencing run. Since only the genomic regions of interest are sequenced, a high depth is
obtained for a relatively low cost. This panel was successfully applied to detect SGD during a
prenatal screening using DNA extracted from amniotic fluid [8]. Because only 4–6 trophoblast
cells can be biopsied in PGT, WGA is required to obtain enough DNA to start the TruSight
One DNA capture. Unfortunately, WGA methods introduce representation bias and nucleo-
tide changes during amplification. This hampers the applicability of these methods in PGT.
Non-uniform amplification of regions across the genome may result in over- or underrepre-
sentation of such genomic regions. Detection of mutations, more specifically SNPs, in insuffi-
ciently amplified (i.e. underrepresented) regions, can introduce genotyping errors.
Additionally, the introduction of errors in the sequence during amplification could result in
mutations being obscured or introduced. The commercially available WGA methods all have
their specific strengths and weaknesses and choice is also influenced by the downstream appli-
cation [9]. WGA methods based on multiple displacement amplification (MDA) are better
suited for SNP detection because they use the high-fidelity phi29 polymerase. PCR-based
WGA methods use DNA polymerases lacking proof-reading ability which introduce more
errors, but yield a more balanced genomic amplification with less over- or underrepresented
regions.
In this study, four different WGA methods were used to amplify DNA isolated from 3
micro-manipulated cells of the well-characterized and extensively sequenced NA12882 cell
line of the Illumina Platinum Genome project. The currently most widely used WGA methods,
two semi-random primer mediated PCR-based methods (SurePlex and MALBAC), a MDA
method (REPLI-g) and a specific primer mediated PCR-based WGA method (Ampli1), were
assessed with subsequent analysis using the TruSight One Sequencing Panel. The performance
assessment is based on SNP calling accuracy, and on the number of allele dropouts. As many
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genetic conditions are multifactorial, and are influenced by multiple genetic variants and hap-
lotypes, this assessment does not provide a performance analysis in terms of genetic diagnosis
accuracy. A thorough clinical validation of this technique will be essential to reveal if WGA
combined with target capture panels such as TruSight One can be used for clinical diagnosis.
Material and methods
Study design
This study was performed on cells from the NA12882 lymphatic male cell line (Coriell Insti-
tute, New Jersey, USA). The DNA of this cell line has been sequenced extensively (50X depth
on a HiSeq2000) and the sequencing data is available online (http://www.illumina.com/
platinumgenomes/). As this data allows for robust SNP detection, the NA12882 genome will
be considered the true control reference in this study. We prepared 14 genomic DNA samples,
each one starting from 3 NA12882 cells. These were amplified by 4 different WGA methods,
resulting in 3 or 5 biological replicates per WGA method (5 for SurePlex, 3 for the others).
Additionally, 4 genomic DNA samples were prepared from larger cell numbers and not sub-
mitted to WGA (further referred to as bulk DNA samples). The bulk DNA samples were
included in the study to evaluate the TruSight kit performance in samples mimicking current
clinical application of the kit [10]. Subsequent capture of gene regions with the TruSight One
Sequencing panel (Illumina, San Diego, CA, USA) was performed on all samples (Fig 1). At
Fig 1. Experimental design. Three cell samples from the NA12882 cell line were amplified with either Ampli1 (3 replicates), REPLI-g (3 replicates), SurePlex (5
replicates) or MALBAC (3 replicates). Subsequently, samples were randomized for TruSight One capture in pools of 3 and those pools were sequenced on separate
MiSeq runs. Four bulk DNA sample from the NA12882 cell line, not amplified before capture, were also randomly included in the pools.
https://doi.org/10.1371/journal.pone.0196334.g001
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the pooling step, four non-amplified bulk DNA samples and the WGA samples were randomly
pooled per 3 to ascertain that variations observed after the capture step are caused either by the
capture step or the preceding WGA. One MiSeq sequencing run was performed per pool of 3
samples.
Growth and isolation of cells
The NA12882 cell line was grown in Roswell Park Memorial Institute (RPMI-1640) medium
(Life technologies, Carlsbad, USA), supplemented with 15% fetal bovine serum (Life technolo-
gies, Carlsbad, USA) and 2mM L-Glutamine. For optimal growth, the cells were incubated at a
temperature of 37˚C and a 5% CO2 level. A known number of cells was isolated with an ergo-
nomic denuding handle from STRIPPER (Origio, Måløv, Denmark) and MXL3-100 needles
with a diameter of 100 μm (Origio, Måløv, Denmark). The desired number of cells was
obtained by a serial dilution using spots of sterile phosphate buffered saline (PBS) (Life tech-
nologies, Carlsbad, USA) on a Petri dish (5.5 cm), performed under an Axiovert 25 light
microscope (Zeiss, Jena, Germany). For optimal lysis, all cells were collected in a maximum
volume of 1 μl. Immediately after collection, all samples were snap frozen in liquid nitrogen.
For each bulk DNA sample, genomic DNA was extracted from 5x106 cells using the DNeasy
Blood & Tissue kit (Qiagen Hilden, Germany).
Whole genome amplification
MALBAC (MALBAC kit, Yikon genomics YK001A/B version 1302.1, Jiangsu, China), Sure-
Plex (Bluegnome, Cambridge, United Kingdom), REPLI-g (Qiagen, Hilden, Germany) and
Ampli1 (Silicon Biosystems, Castel Maggiore, Italy) samples were processed following their
respective kit manufacturer’s instructions. A PBS blank and human positive control DNA
sample was included for each method. All samples were purified using the Genomic DNA
Clean & Concentrator kit (version 1.0.0, Zymo Research, Irvine, USA) according to the manu-
facturer’s instructions with 5 X binding buffer. Concentration was measured using the Qubit
dsDNA High Sensitivity Assay kit (Life technologies, Carlsbad, USA).
Library preparation and sequencing
Sequencing libraries were prepared from 50 ng of the WGA-amplified or bulk DNA using the
TruSight One Sequencing Panel (Illumina, San Diego, CA, USA) according to the manufac-
turer’s instructions, except for the enrichment wash step where a thermocycler was used
instead of the SciGene TruTemp heating system. Probe hybridization and capture was per-
formed on equimolar pools of 3 samples and performed twice. The amount of sequence-able
library fragments was determined by qPCR according to the Sequencing Library qPCR Quan-
tification kit (Illumina, San Diego, USA). Finally, dual-index, paired-end 150 bp sequencing
was performed on a MiSeq (Illumina). All sample pools were sequenced on separate MiSeq
runs.
Data analysis
Sequencing read quality was checked using FastQC (v0.11.5; http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Reads were aligned on the UCSC hg19 reference genome
using bwa (v0.7.5) [11]. Mapping quality was evaluated using Qualimap (v2.2.1) [12]. Dupli-
cate read marking and all bam file manipulations were done using Picardtools (v2.6.0; https://
broadinstitute.github.io/picard/). Reads from the NA12882 Platinum Genome that aligned to
the TruSight One Sequencing Panel regions were isolated using BEDTools (v2.26) [13]. SNP
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discovery in samples and the NA12882 reference was done using GATK (v3.6) [14] according
to best practices instructions. Briefly, base quality scores were recalibrated in a two-pass
covariation analysis supplemented with the dbSNP (release 135) [15] and Mills/1000 Genomes
[16] data sets as a source of known variants. SNP calling was then performed at base resolution
in discovery mode using an emission confidence threshold of 10 and a call confidence thresh-
old of 30. The final SNP’s were obtained by applying the following filter criteria to discard low
quality SNPs: QD< 2.0, FS > 60.0, MQ< 40, MQRankSum < -12.5, ReadPosRankSum <
-8.0. VCFtools (v0.1.13) [17] was used for all SNP comparisons between sample replicates and
the NA12882 reference. Output file parsing, SNP counting and result table generation was
done with python scripts.
Sensitivity, false discovery rate (FDR)
Variants were compared between samples and the reference dataset for positions where both
had sequencing data (comparable SNP’s). Variants not detected in either the sample or the ref-
erence dataset due to lack of sequencing data were counted and labeled as ’no data in sample’
and ‘no data in reference’ respectively. The comparable SNP’s were categorized as follows:
True positives are defined as variant positions found in both the sample and the reference
dataset. False positives are variant positions found in the sample but not in the reference data-
set. Positions called as variants in the reference set but not in the sample are labeled false nega-
tives. The sensitivity for SNP calling in a sample was defined as the number of true positives,
divided by the sum of true positives and false positives. The FDR was defined as the number of
false positives divided by the sum of true positives and false positives.
Results
Coverage and depth
To minimize run bias, samples amplified with the same WGA method were randomized over
different MiSeq runs where possible (Table 1). The number of sequenced reads was variable
between sample replicates. Two Ampli1 samples had a substantial lower yield than the other
samples. This is probably caused by random errors during quantification and equimolar pool-
ing of the sequencing libraries, combined with a variable cluster formation and detection
across different sequencing runs. The percentage of reads aligning to the hg19 reference
genome was similar for all samples including the bulk DNA samples (99.81±0.13%), as was the
read alignment to the TruSight target regions (59.43±4.06%). This capture efficiency reflects
the vendor’s performance specifications of the TruSight One kit. Mean depth across the tar-
geted nucleotides correlated with the read yield and varied from 28X to 96X.
The “coverage uniformity” (Table 1) is calculated as the percentage of targeted base posi-
tions for which the read depth is greater than 0.2 times the mean depth and thus is a measure
for the number of bases that are not underrepresented in the read data. This coverage unifor-
mity was different between the WGA methods, but similar for the repeats within a method. As
expected, the coverage for the bulk DNA samples was most uniform (94.80±0.27%). REPLI-g
amplified samples displayed a coverage uniformity closest to the bulk DNA samples (88.41
±1.01%). The other WGA methods showed a lower uniformity: Ampli1, MALBAC and Sure-
Plex have a uniformity of respectively 49.26±1.33%, 47.23±0.33% and 49.77±1.42%. Fig 2
visualizes this uneven distribution of reads over the targeted regions by means of different
plots. Fig 2A plots the read depth across the targeted regions for one representative sample of
each method. S1 Fig shows the same plots for the other replicate samples. The plot allows the
visualization of larger regions with above or below average read depth. In terms of size of these
alternating larger regions with high and low depth, there seems to be no pronounced
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difference between the different WGA methods. The over- and under-represented regions are
not the same for the different methods, although there are some similarities: Bulk DNA,
Ampli1, REPLI-g and SurePlex have a clear underrepresented region in common. Many of the
over- and under-represented regions overlap between MALBAC and SurePlex. Fig 2B and 2C
show Lorenz curves and Gini indexes describing how sequenced bases are distributed over tar-
geted (B) and covered bases (C). The plots clearly show that the distribution of the reads from
bulk DNA is closest to the even distribution. Comparing the WGA methods, the read distribu-
tion after REPLI-g WGA is closest to the even distribution.
Table 1 also shows the percentage of target regions covered with a minimal depth of 1X,
10X and 20X. For bulk DNA and REPLI-g samples, target region coverage with a minimal
depth of 1X was almost complete (99.61±0.01% and 98.92±0.20% respectively). This percent-
age was at least 20% lower in Ampli1, MALBAC and SurePlex amplified samples. Considering
regions covered with a minimal depth of 10X and 20X, the coverage decreases for all methods.
For bulk DNA, the decrease is smaller compared to the WGA methods. For REPLI-g, the
decrease is smaller compared to the other WGA methods. Fig 3 shows the percentage of tar-
geted bases covered at a read depth between 1 and 60. Again, the plot shows that more targeted
bases are covered at a higher depth when sequencing bulk DNA. Comparing the WGA meth-
ods, REPLI-g results in the highest percentage of targeted bases that are covered at higher
depth. The plot also shows the decline in covered targeted bases when considering higher
depths. This decline is less steep for bulk DNA and REPLI-g compared to the other WGA
methods.
SNP analysis
The online sequencing data for the Platinum Genome of the NA12882 cell line was mapped
against the hg19 reference genome. An in-silico capture was performed on this mapping by
isolating the reads aligning inside TruSight target regions. The SNPs called from this data are
Table 1. Mapping statistics.
Sequencing
run
Read
count
Aligned
reads (%)
Aligned reads on
target (%)
Mean
depth
Coverage
uniformity (%)
Target coverage
at 1X (%)
Target coverage at
10X (%)
Target coverage at
20X (%)
Bulk DNA-1 1 14810732 99.82 60.91 78.85 95.14 99.60 97.38 92.95
Bulk DNA-2 2 15294678 99.92 63.12 83.20 94.82 99.62 97.22 93.07
Bulk DNA-3 3 19477275 99.86 58.25 95.86 94.75 99.62 97.51 94.43
Bulk DNA-4 3 18900774 99.85 59.48 94.65 94.48 99.60 97.36 94.10
Ampli1-1 4 12784447 99.89 57.82 66.23 49.82 75.63 53.00 43.93
Ampli1-2 2 5341335 99.94 66.62 31.01 50.22 65.96 43.59 33.15
Ampli1-3 1 4959973 99.84 62.27 27.48 47.75 63.29 39.59 29.27
MALBAC-1 5 14138090 99.36 52.02 61.03 47.92 78.59 51.27 39.77
MALBAC-2 6 11352373 99.78 61.06 58.21 46.91 78.90 49.68 38.30
MALBAC-3 5 14045595 99.81 53.72 62.62 46.86 78.76 51.39 40.13
REPLI-g-1 1 12359960 99.86 60.33 64.84 87.25 98.70 90.76 79.02
REPLI-g-2 2 13785283 99.92 59.22 71.01 89.10 98.99 92.84 83.18
REPLI-g-3 4 15937788 99.85 56.65 78.98 88.87 99.08 93.61 85.66
SurePlex-1 5 14277005 99.80 64.30 78.17 49.21 78.81 55.51 45.67
SurePlex-2 6 12662797 99.80 51.99 54.81 48.45 75.48 49.85 39.61
SurePlex-3 3 11649675 99.77 64.07 63.49 49.54 77.87 53.12 42.72
SurePlex-4 6 11670489 99.83 59.53 60.40 52.19 55.35 55.35 44.01
SurePlex-5 4 13676160 99.69 58.32 67.39 49.47 82.80 54.15 43.74
https://doi.org/10.1371/journal.pone.0196334.t001
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considered the reference set and were used to calculate the sensitivity and FDR for the samples
(Table 2). The bulk DNA samples closely resembled the reference set, with a 96.8±0.2% sensi-
tivity and a FDR of only 1.5±0.05%. This demonstrates the excellent performance of the
Fig 2. Read distribution. (A) Read depth calculated in 1 kb sliding windows across the concatenated target regions for
one sample of each method. (B, C) Lorenz curves and Gini indexes describing how sequenced bases are distributed
over targeted (B) and covered (C) bases.
https://doi.org/10.1371/journal.pone.0196334.g002
Fig 3. Percent target coverage at various minimum read depths.
https://doi.org/10.1371/journal.pone.0196334.g003
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capture kit when performed on unamplified DNA as specified in the kit’s manual. REPLI-g
amplified samples, with a sensitivity of 93.3±1.5% and FDR of 3.0±1.2%, were the only WGA
samples that performed nearly as good as the bulk DNA samples. All other WGA methods had
a low sensitivity and a high FDR, indicating unreliable results. MALBAC amplified samples
had the lowest sensitivity (65.7±14.3%), and the highest FDR (49.6±15.8%). Ampli1 and Sure-
Plex were positioned somewhere in between. SurePlex had a sensitivity of 74.2±2.2% and an
FDR of 36.8±8.2%, while Ampli1 had a comparable sensitivity of 73.9±0.5% but lower FDR of
20.7±4.2%. SNP analysis reflects the representation bias observed for the Ampli1, MALBAC
and SurePlex samples. REPLI-g is the only WGA method producing SNP discovery results
close to the bulk DNA samples.
The SNP calls were compared within the replicate samples for each WGA method. The 3
REPLI-g replicates had 6688 true positives and 67 false positives in common, comprising 93.7
±1.80% and 32.8±12.05% respectively of the total number of true/false positives for each repli-
cate. Of the common SNP calls, 99.01% are true positives, while 0.99% are false positives.
These results were similar to those of the 4 bulk samples, in which 99.2% of the common SNP
calls are true positives and 0.77% are false positives. This indicates that the detected false posi-
tives are not consistent between all replicates, but are introduced more randomly than true
positives. True positives on the other hand, are highly consistent between these replicates.
These results, as well as those for the other WGA methods are included in S1 Table.
Allele dropout
Allele dropout (ADO), which occurs when one of the sample’s alleles is not present in suffi-
cient quantities for amplification or detection, is a major concern for accurate genotyping.
This results in missing data or spurious homozygotes and in a clinical context it could lead to
misdiagnosis. In S2 Table, we calculated the maximum number of ADOs by summing follow-
ing two situations that could have been caused by ADO: (1) SNP’s that were not called in the
samples due to lack of sequencing data (Table 2, ’No data in sample’). (2) SNP’s that are
Table 2. SNP analysis.
True positives False negatives False positives Sensitivity (%) FDR (%) No data in sample No data in reference
Bulk DNA-1 7480 252 111 96.7 1.5 32 0
Bulk DNA-2 7477 256 108 96.7 1.4 31 0
Bulk DNA-3 7501 226 118 97.1 1.5 37 1
Bulk DNA-4 7479 253 116 96.7 1.5 32 0
Ampli1-1 4415 1517 1501 74.4 25.4 1832 0
Ampli1-2 3762 1327 904 73.9 19.4 2675 0
Ampli1-3 3642 1311 768 73.5 17.4 2811 0
MALBAC-1 3057 3169 6076 49.1 66.5 1538 2
MALBAC-2 4647 1624 2527 74.1 35.2 1493 0
MALBAC-3 4665 1659 4177 73.8 47.2 1440 0
REPLI-g-1 6980 643 325 91.6 4.4 141 4
REPLI-g-2 7199 452 202 94.1 2.7 113 3
REPLI-g-3 7229 438 150 94.3 2.0 97 1
SurePlex-1 4755 1528 3350 75.7 41.3 1481 0
SurePlex-2 4381 1711 3486 71.9 44.3 1672 0
SurePlex-3 4679 1556 2862 75.0 38.0 1529 0
SurePlex-4 4979 1524 1479 76.6 22.9 1261 0
SurePlex-5 4729 1850 2808 71.9 37.3 1185 0
https://doi.org/10.1371/journal.pone.0196334.t002
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heterozygous in the reference, but were called homozygous in the samples. As the latter situa-
tion could also have been caused by amplification or sequencing errors, the calculated number
of ADOs is thus most probably an overestimation. The results show that the bulk DNA sam-
ples have an estimated maximum ADO level of 3.3 to 3.5%. For the WGA methods, the
REPLI-g samples have the lowest ADO (6.7–10.2%). The samples from the MALBAC, Ampli1
and SurePlex WGA methods have ADO between 33.3 and 60.3%.
Discussion
We performed a side-by-side SNP calling performance comparison of 4 widely used WGA
methods in combination with hybridization-capture-based target enrichment sequencing. Per-
formance of the same WGA methods for copy number aberrations (CNA) analyses has been
studied extensively before [2,18–21]. SNP calling performance of these WGA methods in com-
bination with target capture panels has also been studied [19,22,23]: Babayan et al. studied the
accuracy of SNP/mutation, indel, and CNA calling after exome sequencing of Ampli1, REPLI-
g, and PicoPlex WGA products [19]. Liu et al. performed variant calling on limited numbers
of CTCs using GenomePlex and REPLI-g as the WGA methods and the GeneRead DNAseq
Human CRC Panel as the gene panel [22]. SNP variants in CTCs have also been characterized
using Ampli1 WGA and the Ion AmpliSeq Cancer Hotspot Panel v2 [23]. As WGA methods
based on MDA are reportedly [9] better suited for SNP detection because they use the high-
fidelity phi29 polymerase and amplify more regions of the genome compared to PCR-based
methods, it is to be expected that REPLI-g would outperform MALBAC, SurePlex and Ampli1
in this study. Interestingly, a recently published paper by Borgstro¨m et al. [24] compares the
performance of SurePlex, MALBAC, Ampli1 and REPLI-g Mini WGA methods for down-
stream exome capture sequencing starting from single cells. Although their experimental setup
is similar to ours, these authors report that REPLI-g Mini performs worse than the other tested
WGA methods. We can only speculate on the reason underlying these observations and the
discrepancy with our results. Nevertheless, according to the kit manufacturer’s selection guide,
the REPLI-g Mini kit might have been suboptimal for single cell WGA as it recommends start-
ing from at least 10 ng of purified gDNA or from 300 cells. The REPLI-g Single Cell Kit used
in our study allows starting from a single up to 1000 cells or from 10 pg to 10 ng purified
gDNA, which in our 3-cell experiments may have provided us with more robust results.
Conclusion
We compared the performance of 4 WGA methods to unamplified bulk DNA in combination
with the Trusight One capture panel. Our study shows promising results when performing
TruSight One after REPLI-g WGA on 3 cells: SNP calling sensitivity and FDR are similar,
albeit inferior to those obtained using unamplified bulk DNA. Although a thorough clinical
validation is needed to reveal if REPLI-g WGA combined with target capture panels such as
TruSight One can be used for clinical diagnosis, our study shows a promising potential.
Supporting information
S1 Fig. Read distribution. Read depth calculated in 1 kb sliding windows across the
concatenated target regions for replicate 2 and 3 of each method.
(TIF)
S1 Table. SNP detection concordance between replicates per WGA method.
(PDF)
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